Compare HBIO & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBIO | RDI |
|---|---|---|
| Founded | 1901 | 1937 |
| Country | United States | United States |
| Employees | N/A | 2025 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Movies/Entertainment |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 23.6M |
| IPO Year | 2000 | N/A |
| Metric | HBIO | RDI |
|---|---|---|
| Price | $5.11 | $1.09 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.30 | N/A |
| AVG Volume (30 Days) | ★ 327.0K | 20.6K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,176,000.00 | N/A |
| Revenue This Year | $9.13 | N/A |
| Revenue Next Year | $4.21 | $13.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.28 | $0.94 |
| 52 Week High | $0.95 | $1.65 |
| Indicator | HBIO | RDI |
|---|---|---|
| Relative Strength Index (RSI) | 96.73 | 51.86 |
| Support Level | $0.46 | $1.07 |
| Resistance Level | N/A | $1.16 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.28 | 0.01 |
| Stochastic Oscillator | 95.68 | 74.36 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.